A prospective, phase III, multicenter, randomized, investigator-masked, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety and of a generic fixed combination of Brinzolamide 10mg/ml / Timolol 5 mg/ml eye drops suspension versus Azarga®/ALCON 10mg/ml – 5mg/ml eye drops suspension in subjects with open angle glaucoma or ocular hypertension.

PHARMATHEN SA0 个研究点目标入组 216 人开始时间: 2020年6月15日最近更新: 2021年7月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: PHARMATHEN SA
入组人数: 216

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Male or female subjects, of any race or ethnicity, aged = 18 years
•In case of women, postmenopausal (>12 months without menstrual bleeding), surgically sterilized, or using effective birth control measures.
•2.Subjects diagnosed with bilateral or unilateral open angle glaucoma or ocular hypertension in at least one eye
•Subjects may be naïve to antiglaucoma medications or treated for their elevated IOP, which however is insufficiently controlled either on monotherapy or on two IOP-lowering medications.
•3.Mean IOP measurements for = 1 eye (the same eye) must be 24 - 36 mm Hg at 08:00 a.m. and 21 - 36 mm Hg at 10:00 a.m. and 16:00 p.m. during the baseline visit (following the required washout period for non-naïve patients)
•4.Mean IOP = 36 mm Hg in both eyes at all time points of the baseline visit.
•5.Without treatment for open angle glaucoma with IOP-lowering drugs for at least as many days as appropriate by the washout schedule. For subjects not taking any IOP-lowering medications, this time-period should be 3 ± 1 days.
•6.Best corrected visual acuity of = 20/100 (Snellen chart) corresponding to logMAR score of 0.7.
•7.Subjects able to understand the requirements of the clinical trial and to agree to return for the follow-up visits.
•8.Subjects willing to provide voluntary written informed consent and data protection declaration before any clinical trial-related procedure is performed.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 108
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 108

排除标准

•Related to the eye:
•1.History of chronic, recurrent or current severe inflammatory eye disease (i.e. scleritis, uveitis, herpes keratitis) in either eye.
•2.Any form of glaucoma other than open angle glaucoma with glaucomatous optic disc morphology or glaucoma visual field defects, such as pigmentary or pseudo-exfoliating glaucoma.
•3.Schaffer angle grade < 2 in either eye (range, 0 [complete or partial closure] to 3 [ wide open angle, > 20o]), as measured by gonioscopy.
•4.Cup-to-disc ratio > 0.80 (horizontal or vertical measurement) in either eye.
•5.Severe central visual field loss (i.e. sensitivity = 10 dB in = 2 of the 4 visual field test points closer to the point of fixation) in either eye.
•6.Best corrected visual acuity = 20/100 (Snellen chart) corresponding to worse than 0.7 logarithm of minimal angle or resolution (logMAR) score.
•7.Central corneal thickness > 620 µm, as measured by pachymetry, in either eye.
•8.Any corneal abnormalities or any abnormality that will preclude accurate and reliable IOP reading with an applanation tonometer.
•9.Pupil with inadequate ability to dilate sufficiently for peripheral retinal examination.
•10.Clinically significant or progressive retinal disease (e.g. retinal degeneration, diabetic retinopathy, retinal detachment) in either eye
•11.History of anterior chamber intra-ocular lens, torn posterior lens capsule, aphakia or any known risk factor for cystoid macular edema.
•12.Ocular pathology in either eye (including severe dry eye) that may prohibit the administration of an a-adrenergic agonist and/or a topical carbonic anhydrase inhibitors (CAIs)
•13.Inability to safely discontinue use of or go without IOP-lowering ocular medications as per the washout schedule.
•14.Intraocular surgery = 6 months before the study
•15.Ocular laser surgery = 3 months before the study
•Related to systemic health
•16.<30-day stable dosing regimen before the screening visit of any long-term systemic medication or substance that may affect IOP (e.g. ß-blockers, calcium channel blockers, angiotensin converting enzyme ([ACE] inhibitors, prostaglandins, clonidine)
•17.Use of high-dose (>1 g daily) salicylate therapy, = 4 weeks before the baseline visit.
•18.Therapy with another investigational agent = 30 days before the screening visit.
•19.Concurrent use of a MAO inhibitor, any additional systemic or topical ocular hypotensive medications or glucocorticoid (topical or systemic) medications.
•20.Current use of topical, ocular non-steroidal anti-inflammatory medications.
•21.Treatment with oral carbonic anhydrase inhibitors (e.g. acetazolamide, methazolamide, topiramate, sultiame, zonisamide)
•22.Current or anticipated treatment with psychotropic medications that augment adrenergic response (e.g. dopamine, amitriptyline).
•23.Active or prior, severe, unstable, or uncontrolled cardiovascular (sinus bradycardia, sick sinus syndrome, sinoatrial block, second or third degree atrioventricular block not controlled with pacemaker, overt cardiac failure, cardiogenic shock), reactive airway disease (bronchial asthma or a history of bronchial asthma, severe COPD) or renal disease (severe renal insufficiency [creatinine clearance < 30 ml/min) or hyperchloremic acidosis) that would prevent safe administration of topical a-adrenergic agonists or carbonic anhydrase inhibitors, according to the Investigator’s judgement.
•24.Hypersensitivity to timolol, topical or oral CAIs (brinzolamide), sulfonamide derivatives or any comp

研究者

发起方

PHARMATHEN SA

相似试验

招募中

1 期

A trial that aims to compare the efficacy and safety of two treatments for open-angle glaucoma or ocular hypertension. Both drugs contain the same active substance (Brinzolamide 10 mg/ml Eye Drops, Suspension). The patients will be followed for a certain period of time and will receive on a random principle either the new drug or the authorized drug. The trial will be conducted in several centers. The investigators will not know which patient is using a test and which reference product.

EUCTR2022-002524-12-BGAZAD Pharma AG244

进行中（未招募）

1 期

A prospective, phase III, multicenter, randomized, investigator-masked, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety and of a generic fixed combination of Brinzolamide 10mg/ml / Timolol 5 mg/ml eye drops suspension versus Azarga®/ALCON 10mg/ml – 5mg/ml eye drops suspension in subjects with open angle glaucoma or ocular hypertension.open-angle glaucoma or ocular hypertensionMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disorders

EUCTR2019-000921-39-GRPHARMATHEN SA216

进行中（未招募）

1 期

To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).Complicated urinary tract infection

EUCTR2017-003772-31-BGIterum Therapeutics International Limited1,381

进行中（未招募）

1 期

EUCTR2017-003772-31-LVIterum Therapeutics International Limited1,381

进行中（未招募）

1 期

EUCTR2017-003772-31-HUIterum Therapeutics International Limited1,156